PDCD1 and prostate carcinoma: In wild‐type (WT) mice bearing experimental RM1 prostate cancer lung metastases (Figure 2a) or B16F10 melanoma lung metastases (Figure 2b), combination of the control anti‐RANKL (anti‐RANKL IgG1D265A) and anti‐PD‐1 (anti‐PD‐1 IgG1D265A) antibodies significantly improved metastatic control compared with anti‐PD‐1 treatment alone.